3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
Neoplasms
10
Multiple Myeloma
8
Prostatic Neoplasms
6
Neoplasm Metastasis
5
Giant Cell Tumor of Bone
5
Fractures, Bone
4
Recurrence
3
Osteoporosis
3
Bone Neoplasms
3
Bone Diseases, Metabolic
3
Spinal Cord Compression
2
Smoldering Multiple Myeloma
2
Parathyroid Neoplasms
2
Lymphoma
2
Kidney Neoplasms
2
Giant Cell Tumors
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Mastocytosis, Systemic
1
Lymphoma, Non-Hodgkin
1
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
Chemotherapy, Adjuvant
5
Cyclophosphamide
4
Trastuzumab
3
Tamoxifen
3
Letrozole
3
Doxorubicin
3
Brachytherapy
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
pertuzumab
2
Surgical Procedures, Operative
2
Radiotherapy, Conformal
2
Magnetic Resonance Spectroscopy
2
Epirubicin
2
talimogene laherparepvec
1
sargramostim
1
palbociclib
1
ferric carboxymaltose
1
atezolizumab
1
atamestane
1
aldesleukin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
VPS Coriolus versicolor extract
1
Toremifene
1
Thiotepa
1
Therapeutics
1
Reverse Transcriptase Polymerase Chain Reaction
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Ductal, Breast
×
Denosumab
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled